

08 Oct 2021 | Analysis

Device Week, 8 October 2021 – Boston Scientific Acquisition, And Poor SPAC Float

by [Reed Miller](#)

In this edition of Device Week, *Medtech Insight's* Reed Miller discusses Boston Scientific's acquisition of Baylis, and what it means for its heart business. UK-based reporter Barnaby Pickering looks into LumiraDX's recent float on the stock market, and why it might have been so poorly received.

Listen to the podcast via the player below:

[Click here to explore this interactive content online](#) 

The archive of Device Week and the rest of Informa Pharma Intelligence's podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#), [Spotify Podcasts](#) and via smart speakers if one of these platforms has been set up as your default podcast provider.

Medtech Insight articles addressing topics discussed in this episode:

- [Boston Scientific Continues Acquisition Streak With \\$1.75Bn Deal For Baylis' Cardiology Products](#)
- [LumiraDX Goes Public In SPAC Merger](#) (Free Article)